Smoldering Multiple Myeloma
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early int...
Source: Hematology/Oncology Clinics of North America - December 28, 2023 Category: Cancer & Oncology Authors: S. Vincent Rajkumar, P. Leif Bergsagel, Shaji Kumar Source Type: research
Diallyl disulfide synergizes with melphalan to increase apoptosis and DNA damage through elevation of reactive oxygen species in multiple myeloma cells
AbstractDiallyl disulfide (DADS), one of the main components of garlic, is well known to have anticancer effects on multiple cancers. However, its efficacy in treating multiple myeloma (MM) is yet to be determined. We explored the effects of DADS on MM cells and investigated the synergistic effects of DADS when combined with five anti-MM drugs, including melphalan, bortezomib, carfilzomib, doxorubicin, and lenalidomide. We analyzed cell viability, cell apoptosis, and DNA damage to determine the efficacy of DADS and the drug combinations. Our findings revealed that DADS induces apoptosis in MM cells through the mitochondria...
Source: Annals of Hematology - December 27, 2023 Category: Hematology Source Type: research
Development of Phenyl-substituted Isoindolinone- and Benzimidazole-Type Cereblon Ligands for Targeted Protein Degradation
Chembiochem. 2023 Dec 20:e202300685. doi: 10.1002/cbic.202300685. Online ahead of print.ABSTRACTThalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4CRBN to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, which exert high selectivity over the well-kno...
Source: Chembiochem - December 20, 2023 Category: Biochemistry Authors: Xueqing Nie Yu Zhao Hua Tang Zhongrui Zhang Junzhuo Liao Chelsi M Almodovar-Rivera Ramya Sundaresan Haibo Xie Le Guo Bo Wang Hongqing Guan Yongna Xing Weiping Tang Source Type: research
Development of Phenyl-substituted Isoindolinone- and Benzimidazole-Type Cereblon Ligands for Targeted Protein Degradation
Chembiochem. 2023 Dec 20:e202300685. doi: 10.1002/cbic.202300685. Online ahead of print.ABSTRACTThalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4CRBN to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, which exert high selectivity over the well-kno...
Source: Chembiochem - December 20, 2023 Category: Biochemistry Authors: Xueqing Nie Yu Zhao Hua Tang Zhongrui Zhang Junzhuo Liao Chelsi M Almodovar-Rivera Ramya Sundaresan Haibo Xie Le Guo Bo Wang Hongqing Guan Yongna Xing Weiping Tang Source Type: research
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
Leukemia, Published online: 20 December 2023; doi:10.1038/s41375-023-02113-6Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7 (Source: Leukemia)
Source: Leukemia - December 20, 2023 Category: Hematology Authors: Michael C. Kann Emily M. Schneider Antonio J. Almazan Isabel C. Lane Amanda A. Bouffard Valentina M. Supper Hana N. Takei Alexander Tepper Mark B. Leick Rebecca C. Larson Benjamin L. Ebert Marcela V. Maus Max Jan Source Type: research
Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis
In conclusion, post-transplantation therapy improved PFS and contributed to sustained MRD-negativity in myeloma patients.PMID:38103160 | DOI:10.1007/s12185-023-03682-z (Source: International Journal of Hematology)
Source: International Journal of Hematology - December 16, 2023 Category: Hematology Authors: Kazuhito Suzuki Tadahiro Gunji Masaharu Kawashima Hideki Uryu Riku Nagao Mamiko Momoki Hiroki Yokoyama Hiroto Ishii Susumu Tanoue Takeshi Saito Kaichi Nishiwaki Shingo Yano Source Type: research
Detection of lenalidomide metabolites in urine to discover drug-resistant compounds
Clin Chim Acta. 2023 Dec 14:117707. doi: 10.1016/j.cca.2023.117707. Online ahead of print.ABSTRACTLenalidomide is the first-line drug for the clinical treatment of multiple myeloma. However, its efficacy differs significantly among patients. Clinically, after lenalidomide treatment, few patients' conditions worsened, whereas others remained stable or improved. To clarify the reasons for this difference in efficacy, 20 patients with multiple myeloma who received maintenance treatment with lenalidomide were retrospectively included in this study. Lenalidomide metabolic compounds were detected in patient urine using mass spec...
Source: International Journal of Clinical Chemistry - December 16, 2023 Category: Chemistry Authors: Xiaokai Zhan Xikun Liu Li Rang Man Shen Jiajia Zhang Ran Tang Sibin Fan Fengyi Zhao Xin Li Xiaoying Zhang Zhongxia Huang Sen Zhang Source Type: research
Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis
In conclusion, post-transplantation therapy improved PFS and contributed to sustained MRD-negativity in myeloma patients.PMID:38103160 | DOI:10.1007/s12185-023-03682-z (Source: International Journal of Hematology)
Source: International Journal of Hematology - December 16, 2023 Category: Hematology Authors: Kazuhito Suzuki Tadahiro Gunji Masaharu Kawashima Hideki Uryu Riku Nagao Mamiko Momoki Hiroki Yokoyama Hiroto Ishii Susumu Tanoue Takeshi Saito Kaichi Nishiwaki Shingo Yano Source Type: research
